The Skidki-na-vse® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Study offers a new perspective on the molecular events that may lead some individuals to develop multiple sclerosis.
The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.
Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis.
New updates to immunization guidelines in multiple sclerosis outline recommendations on vaccination decisions for patients.
Dietary interventions that raise levels of high-density lipoprotein, or good cholesterol, may affect fatigue symptoms in multiple sclerosis.
Top news of the day from across the health care landscape.
Rising drug prices for disease-modifying therapies resulted in substantial increases in spending for Medicare beneficiaries with multiple sclerosis.
Istradefylline tablets (Nourianz, Kyowa Kirin) are indicated to assist patients who are experiencing 'off' episodes, better defined as a time when a patient’s medications are not working well.
Patients with progressive multiple sclerosis who were placed on the Wahls diet, which is high in fruits and vegetables, found to experience improved fatigue levels.
The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigourous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.
The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigorous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.
Rewind Therapeutics, a private Belgian biotech company developing remyelinating therapies for myelin-affecting diseases, has been awarded a €2.9 million grant from Flanders Innovation and Entrepreneurship (VLAIO) for a new industry-academic research and development collaboration.
+ Load More